Why is the 1 yr estimated around $38.95 on AZN?
estimated 39% of revs will be off patent by 2012
nomorehomes - I know they have some patentys coming off patents soon. But, I do not think it is this high. To support your statment, can you please how you got this 37% and which drug and how much and so on? Thanks
This is what AZN management says:"The Anglo-Swedish drugmaker bolstered its positive outlook with a decision to lift full year earnings per share forecast to a range of $5.70 to $6 from $5.15-$5.45."------------------------------On that basis, AZN is easily a $70 stock.No reason to consider otherwise.After all, management has a great habit of beating estimates consistently.Additionally, AZN pipeline is growing with 322 clinical trials in active stages and 22 trials under Medimmune for a total of 344 FDA clinical trials in USA and not including EU and UK trials.